Parasomnias in adults

Patients with violent parasomnias are followed up closely to make sure that the treatment administered is effective and well tolerated.

• Rapid eye movement sleep disorder patients are evaluated 1 month after initiation of treatment and then followed every 3-6 months to ensure continued efficacy of clonazepam and compliance.

• Patients taking antidepressant medicine to treat parasomnias should be closely monitored for evidence of suicidal ideation, especially younger patients on such medicines.

• Because fibrotic complications such as pleural and peritoneal fibrosis have been observed very rarely with dopamine agonist therapy (particularly the ergot dopamine agonists such as bromocriptine, pergolide, and cabergoline, rather than the non-ergot dopamine agonists such as pramipexole and ropinirole), patients should be monitored for symptoms related to such pathology.